ClinicalTrials.gg
TerminatedNCT00101907Updated Mar 20, 2014Results posted

Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer

A Phase 1 interventional study of AMG 706 and Panitumumab in Lung Cancer, Pancreatic Cancer and Esophageal Cancer, sponsored by Amgen. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-20.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Why this study was terminated
Study terminated per recommendation of Data Review Team

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing gemcitabine in Lung Neoplasms — 2 open to participants now, 3 under way, 1 of them phase 3. Gemcitabine · Lung Neoplasms.

Enrollment
43rd of 78
41 · median 47
Started
2004
with 7 others
Phase 1
9 of 94
none open now
Registered
39th of 94
by date

Among the 94 studies testing gemcitabine in Lung Neoplasms, this one is the 43rd largest by enrollment of the 78 interventional ones that give a count, is one of 8 that started in 2004, is one of 9 in phase 1, and was the 39th registered.

Lung Neoplasms

5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

2 of the 94 studies testing gemcitabine in Lung Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing gemcitabine in Lung Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with gemcitabine and cisplatin chemotherapy. This is a Phase 1b clinical study.

03

Conditions studied

  • Lung Cancer
  • Pancreatic Cancer
  • Esophageal Cancer

Keywords

  • Advanced Cancer
  • AMG 706
  • Panitumumab
  • Gemcitabine-Cisplatin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For complete inclusion and exclusion, please refer to the investigator.

Inclusion criteria

Inclusion Criteria:

  • Competent to comprehend, sign, and date an Institutional Review Board (IRB) approved form
  • Subjects with advanced cancer in whom the gemcitabine and cisplatin chemotherapy regimen is clinically indicated
  • (ECOG) performance status of 0 or 1
  • Adequate hematological function
  • Adequate renal function
  • Adequate hepatic function
  • of greater than or equal to 3 months as documented by the investigator

Exclusion criteria

Exclusion Criteria:

  • More than 1 prior chemotherapy regimen
  • History of venous thrombosis
  • Myocardial infarction, cerebrovascular accident, , percutaneous transluminal coronary angioplasty/stent, or unstable angina within 1 year before study enrollment
  • History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on screening chest computed tomograph (CT) scan
  • Average systolic blood pressure of greater than 145 mm Hg or average diastolic blood pressure of greater than 85 mm Hg
  • Radiotherapy within 28 days of study enrollment or within 14 days of study enrollment for peripheral lesions
  • Prior AMG 706, panitumumab, or another anti-EGFr monoclonal antibody (mAb) (e.g., cetuximab [Erbitux®] or EMD 72000)
  • Systemic chemotherapy within 28 days before study enrollment
  • Major surgery within 28 days or minor surgery within 14 days of study enrollment
  • Central nervous system (Exception: subjects with treated asymptomatic central nervous system metastases, those who have been clinically stable in the judgment of the investigator and off for at least 30 days before the study enrollment are eligible)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Panitumumab + Gem/Cis

    Panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.

    Biological: Panitumumab · Drug: Gemcitabine · Drug: Cisplatin

  • Experimental
    50 mg QD AMG 706 + panitumumab + Gem/Cis

    AMG 706 50 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.

    Drug: AMG 706 · Biological: Panitumumab · Drug: Gemcitabine · Drug: Cisplatin

  • Experimental
    75 mg QD AMG 706 + panitumumab + Gem/Cis

    AMG 706 75 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.

    Drug: AMG 706 · Biological: Panitumumab · Drug: Gemcitabine · Drug: Cisplatin

  • Experimental
    100 mg QD AMG 706 + panitumumab + Gem/Cis

    AMG 706 100 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.

    Drug: AMG 706 · Biological: Panitumumab · Drug: Gemcitabine · Drug: Cisplatin

  • Experimental
    125 mg QD AMG 706 + panitumumab + Gem/Cis

    AMG 706 125 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.

    Drug: AMG 706 · Biological: Panitumumab · Drug: Gemcitabine · Drug: Cisplatin

  • Experimental
    75 mg BID AMG 706 + panitumumab + Gem/Cis

    AMG 706 75 mg administered orally twice daily (BID) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.

    Drug: AMG 706 · Biological: Panitumumab · Drug: Gemcitabine · Drug: Cisplatin

Interventions

  • AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.

  • BiologicalPanitumumab

    Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.

    Also known as: Vectibix

  • Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.

    Also known as: Gemzar

  • Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.

    Also known as: cisplatinum, cis-diamminedichloridoplatinum(II) (CDDP)

06

What researchers measure

Primary outcomes

  1. Participant Incidence of Adverse Events

    The number of participants who experienced at least one treatment-emergent adverse event. Additional details regarding specfic adverse events are provided in the Adverse Event section of this posting.

    Time frame: From the first dose of any study treatment until 30 days after the last dose of study treatment, up to a maximum of 509 days.

Secondary outcomes

  1. Number of Participants With an Objective Tumor Response

    The number of participants with a confirmed objective tumor response, defined as a complete response (CR) or partial response (PR) throughout based on modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Any CR or PR was to be confirmed 4 to 6 weeks after the initial CR or PR.

    Time frame: From enrollment until date of last follow-up visit. The median follow-up time was 24 weeks, with a range of 3 to 73 weeks.

  2. Tmax

    Time after dosing when maximum plasma concentration was observed for AMG 706

    Time frame: Day 1, pre-dose and at 1, 3, 6,12 (BID cohort only) and 24 hours post-dose.

  3. Cmax

    The maximum observed plasma concentration after AMG 706 dosing

    Time frame: Day 1, pre-dose and at 1, 3, 6,12 (BID cohort only) and 24 hours post-dose.

  4. AUC0-24

    Area under the plasma concentration-time curve from time 0 to 24 hours postdose (AUC0-24) with AMG 706. AUC0-24 was estimated using the linear/log trapezoidal method. For the BID cohort, AUC0 24 was estimated as 2 times the AUC from time 0 to 12 hours post the first daily dose (AUC0-12) using the linear/log trapezoidal method.

    Time frame: Day 1, pre-dose and at 1, 3, 6,12 (BID cohort only) and 24 hours post-dose.

  5. AUC0-inf

    Area under the concentration-time curve from time 0 to infinite time (AUC0-inf) postdose with AMG 706. AUC0-inf was estimated using the linear/log trapezoidal method. AUC0-inf was not calculated for the BID cohort.

    Time frame: Day 1, pre-dose and at 1, 3, 6,12 (BID cohort only) and 24 hours post-dose.

07

Results

Posted Mar 20, 2014

Participant flow

Participants were enrolled from 2 December 2004 through 7 March 2007. This study was designed with two parts. However, Part 2 was not conducted due to safety issues found in Part 1. Thus Part 1 is referenced as the overall study here.

Participant flow — Overall Study
MilestonePanitumumab + Gem/Cis50 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg QD AMG 706 + Panitumumab + Gem/Cis100 mg QD AMG 706 + Panitumumab + Gem/Cis125 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg BID AMG 706 + Panitumumab + Gem/Cis
Started8866112
Completed675562
Not completed211150
Withdrew: Adverse event100000
Withdrew: Death010030
Withdrew: Physician decision000110
Withdrew: Withdrawal by subject101010

Outcome measures

SecondaryNumber of Participants With an Objective Tumor Response

The number of participants with a confirmed objective tumor response, defined as a complete response (CR) or partial response (PR) throughout based on modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Any CR or PR was to be confirmed 4 to 6 weeks after the initial CR or PR.

Time frame:
From enrollment until date of last follow-up visit. The median follow-up time was 24 weeks, with a range of 3 to 73 weeks.
Reported as:
Number · participants
Number of Participants With an Objective Tumor Response
participantsPanitumumab + Gem/Cis50 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg QD AMG 706 + Panitumumab + Gem/Cis100 mg QD AMG 706 + Panitumumab + Gem/Cis125 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg BID AMG 706 + Panitumumab + Gem/Cis
Number of Participants With an Objective Tumor Response201421
SecondaryTmax

Time after dosing when maximum plasma concentration was observed for AMG 706

Time frame:
Day 1, pre-dose and at 1, 3, 6,12 (BID cohort only) and 24 hours post-dose.
Reported as:
Median · hours
Tmax
hours50 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg QD AMG 706 + Panitumumab + Gem/Cis100 mg QD AMG 706 + Panitumumab + Gem/Cis125 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg BID AMG 706 + Panitumumab + Gem/Cis
Tmax1.00 (1.00 to 3.00)1.00 (1.00 to 3.00)1.38 (1.00 to 3.00)1.00 (1.00 to 3.00)1.00 (1.00 to 1.00)
SecondaryCmax

The maximum observed plasma concentration after AMG 706 dosing

Time frame:
Day 1, pre-dose and at 1, 3, 6,12 (BID cohort only) and 24 hours post-dose.
Reported as:
Mean · ng/mL
Cmax
ng/mL50 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg QD AMG 706 + Panitumumab + Gem/Cis100 mg QD AMG 706 + Panitumumab + Gem/Cis125 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg BID AMG 706 + Panitumumab + Gem/Cis
Cmax152 ± 78186 ± 92278 ± 90458 ± 208268 ± NA
SecondaryAUC0-24

Area under the plasma concentration-time curve from time 0 to 24 hours postdose (AUC0-24) with AMG 706. AUC0-24 was estimated using the linear/log trapezoidal method. For the BID cohort, AUC0 24 was estimated as 2 times the AUC from time 0 to 12 hours post the first daily dose (AUC0-12) using the linear/log trapezoidal method.

Time frame:
Day 1, pre-dose and at 1, 3, 6,12 (BID cohort only) and 24 hours post-dose.
Reported as:
Mean · μg*hr/mL
AUC0-24
μg*hr/mL50 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg QD AMG 706 + Panitumumab + Gem/Cis100 mg QD AMG 706 + Panitumumab + Gem/Cis125 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg BID AMG 706 + Panitumumab + Gem/Cis
AUC0-241.03 ± 0.501.31 ± 0.512.38 ± NA2.82 ± 1.022.54 ± NA
SecondaryAUC0-inf

Area under the concentration-time curve from time 0 to infinite time (AUC0-inf) postdose with AMG 706. AUC0-inf was estimated using the linear/log trapezoidal method. AUC0-inf was not calculated for the BID cohort.

Time frame:
Day 1, pre-dose and at 1, 3, 6,12 (BID cohort only) and 24 hours post-dose.
Reported as:
Mean · μg*hr/mL
AUC0-inf
μg*hr/mL50 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg QD AMG 706 + Panitumumab + Gem/Cis100 mg QD AMG 706 + Panitumumab + Gem/Cis125 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg BID AMG 706 + Panitumumab + Gem/Cis
AUC0-inf1.12 ± 0.521.64 ± 0.482.59 ± NA3.05 ± 1.34—
PrimaryParticipant Incidence of Adverse Events

The number of participants who experienced at least one treatment-emergent adverse event. Additional details regarding specfic adverse events are provided in the Adverse Event section of this posting.

Time frame:
From the first dose of any study treatment until 30 days after the last dose of study treatment, up to a maximum of 509 days.
Reported as:
Number · Participants
Participant Incidence of Adverse Events
ParticipantsPanitumumab + Gem/Cis50 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg QD AMG 706 + Panitumumab + Gem/Cis100 mg QD AMG 706 + Panitumumab + Gem/Cis125 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg BID AMG 706 + Panitumumab + Gem/Cis
Participant Incidence of Adverse Events8866112

Adverse events

Collected over From the first dose of any study treatment until 30 days after the last dose of study treatment, up to a maximum of 509 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab + Gem/Cis—2/8 (25%)8/8 (100%)
50 mg QD AMG 706 + Panitumumab + Gem/Cis—4/8 (50%)8/8 (100%)
75 mg QD AMG 706 + Panitumumab + Gem/Cis—3/6 (50%)6/6 (100%)
100 mg QD AMG 706 + Panitumumab + Gem/Cis—4/6 (66.7%)6/6 (100%)
125 mg QD AMG 706 + Panitumumab + Gem/CisEdit—9/11 (81.8%)11/11 (100%)
75 mg BID AMG 706 + Panitumumab + Gem/CisEdit—1/2 (50%)2/2 (100%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventPanitumumab + Gem/Cis50 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg QD AMG 706 + Panitumumab + Gem/Cis100 mg QD AMG 706 + Panitumumab + Gem/Cis125 mg QD AMG 706 + Panitumumab + Gem/CisEdit75 mg BID AMG 706 + Panitumumab + Gem/CisEdit
Arterial thrombosisVascular disorders0/80/80/60/61/111/2
DehydrationMetabolism and nutrition disorders1/81/80/60/63/110/2
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/81/81/61/63/110/2
Deep vein thrombosisVascular disorders0/82/80/61/62/110/2
DiarrhoeaGastrointestinal disorders0/80/80/60/62/110/2
AnaemiaBlood and lymphatic system disorders0/81/80/61/60/110/2
ThrombocytopeniaBlood and lymphatic system disorders1/80/80/61/60/110/2
Angina pectorisCardiac disorders0/80/81/60/60/110/2
CardiomyopathyCardiac disorders0/80/80/61/60/110/2
Oesophageal perforationGastrointestinal disorders0/80/81/60/60/110/2
Most frequent other events
Showing 10 of 246
Most frequent other events
EventPanitumumab + Gem/Cis50 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg QD AMG 706 + Panitumumab + Gem/Cis100 mg QD AMG 706 + Panitumumab + Gem/Cis125 mg QD AMG 706 + Panitumumab + Gem/CisEdit75 mg BID AMG 706 + Panitumumab + Gem/CisEdit
NauseaGastrointestinal disorders6/86/85/66/610/111/2
FatigueGeneral disorders5/87/83/64/610/112/2
HypomagnesaemiaMetabolism and nutrition disorders2/83/83/63/66/112/2
ErythemaSkin and subcutaneous tissue disorders5/85/86/65/63/111/2
PruritusSkin and subcutaneous tissue disorders5/82/85/65/60/112/2
RashSkin and subcutaneous tissue disorders6/85/82/64/63/112/2
AnaemiaBlood and lymphatic system disorders6/85/82/65/64/111/2
NeutropeniaBlood and lymphatic system disorders4/85/84/65/63/110/2
Mucosal inflammationGeneral disorders4/81/80/65/61/110/2
CoughRespiratory, thoracic and mediastinal disorders0/81/85/61/62/110/2

Baseline characteristics

Age, Continuous
Age, Continuous(years)Panitumumab + Gem/Cis50 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg QD AMG 706 + Panitumumab + Gem/Cis100 mg QD AMG 706 + Panitumumab + Gem/Cis125 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg BID AMG 706 + Panitumumab + Gem/CisTotal
Mean55.5 ± 12.460.4 ± 13.856.0 ± 13.351.5 ± 13.561.1 ± 8.365.0 ± 17.057.9 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab + Gem/Cis50 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg QD AMG 706 + Panitumumab + Gem/Cis100 mg QD AMG 706 + Panitumumab + Gem/Cis125 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg BID AMG 706 + Panitumumab + Gem/CisTotal
Female43245018
Male45426223
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Panitumumab + Gem/Cis50 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg QD AMG 706 + Panitumumab + Gem/Cis100 mg QD AMG 706 + Panitumumab + Gem/Cis125 mg QD AMG 706 + Panitumumab + Gem/Cis75 mg BID AMG 706 + Panitumumab + Gem/CisTotal
Black or African American1120004
Hispanic or Latino1000001
White or Caucasian674611236
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Burris H, Stephenson J, Otterson GA, Stein M, McGreivy J, Sun YN, Ingram M, Ye Y, Schwartzberg LS. Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer. J Oncol. 2011;2011:853931. doi: 10.1155/2011/853931. Epub 2011 Apr 14. PubMed 21559248 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of Jun 2007 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 6 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2005
First posted
Jan 19, 2005
Start
Dec 2004
Primary completionActual
Jun 2007
CompletionActual
Apr 2008
Results first posted
Mar 20, 2014
Last update
Mar 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00101907
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 19, 2005
Start date
Dec 2004
Primary completion
Jun 2007
Completion
Apr 2008
Results posted
Mar 20, 2014
Last update
Mar 20, 2014

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Panitumumab · Gemcitabine · Cisplatin

Start the discussion